Special Issue

Finding Innovative Targets and Mechanisms While Discovering Novel Antimicrobial Agents

Message from the Guest Editor

Antimicrobial resistance remains a critical and urgent need for public health, and the actual COVID-19 pandemic has further stressed this serious problem. Among the most common multidrug-resistant bacteria, the acronym ESKAPE was ad hoc invented, referring to the most virulent and antibiotic-resistant pathogen strains: Enterococcus faecium. Staphylococcus aureus. Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. These Gram-positive and Gram-negative strains are the major cause of life-threatening infections. The general inefficacy of commonly used antibiotics raises the importance of developing new antibacterial agents having an innovative and effective mechanism of action, able to counter the emergence of resistance. With this Special Issue, all scientists working on antimicrobial agents, specifically those focusing on innovative targets and mechanisms of action, in infectious diseases caused by bacteria, parasites, viruses, and fungi are invited to contribute submissions. All manuscripts dealing with the design and synthesis, biological evaluation, and target validation of novel antimicrobials are welcome.

Guest Editor

Dr. Valentina Straniero

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Luigi Mangiagalli, 25, 20133 Milan, Italy

Deadline for manuscript submissions

closed (31 October 2022)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/104056

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

